The nation of Zimbabwe has turned down a substantial American healthcare agreement valued at $367m (£272m) spanning five years over Washington's demand for confidential biological samples.
This rejection became public after a official document from December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the deal was "unbalanced".
A government spokesman has since explained that the US was seeking health data for scientific study and commercial gain but refused to share the resulting advantages from any future vaccines.
"We must now begin the difficult and regrettable process of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had provided more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for more negotiations to find a deal agreeable to both sides so the country's critical HIV programme can continue.
Wider Context
This rejection comes after a comparable case in Kenya, where a high court suspended a related deal with the US after legal challenges were filed about the security of Kenyans' health data.
After returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump stated its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to boost transparency and accountability.
According to statements, Sixteen nations in Africa have so far signed similar health pacts, representing over $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration could have provided significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on antiretroviral therapy via American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to surrender its genetic material and health information over an extended period, with no corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"In essence, our nation would supply the raw materials for scientific discovery with no certainty that the resulting innovations would be accessible to our people if a future disease outbreak emerge."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its pursuit of one-on-one deals were undermining systems already established via the international organization.
Mangwana cited its Pandemic Benefit-Sharing framework designed to manage future global health emergencies.
"This system is intended to ensure that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to develop them."
These objections over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We welcome further dialogue with our US partners on how future co-operation could be designed in a way that honours the independence and dignity of each country."
Medical Community Response
Medical experts expressed it acknowledged the official position, but recommended that negotiations need to persist given that a large portion of the nation's Aids initiatives depended on international support.
"Where technical issues arise, including those involving information security or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," it said.
The halted deal highlights the continuing debate between accepting crucial international aid and safeguarding local interests in an ever more data-driven world.